Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes
    • The Product Book

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
    • Content Hubs
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2026 / April / Why a Popular AntiAging Compound May Also Fuel Cancer
Omics Proteomics News and Research Mass Spectrometry Metabolomics & Lipidomics

Why a Popular Anti-Aging Compound May Also Fuel Cancer

Proteomics and metabolic assays show how spermidine-linked signaling diverges in healthy and malignant cells

04/01/2026 2 min read

Share

Polyamines have become familiar players in longevity research, with spermidine in particular attracting attention for its ability to stimulate autophagy and support mitochondrial function. But a new study shows that the same molecules can also drive cancer cell growth – through a distinct pathway centered on the translation factor eIF5A2.

Researchers at Tokyo University of Science set out to resolve this apparent contradiction using HeLa and breast cancer cell lines, combining polyamine depletion and rescue experiments with large-scale proteomics, transcriptomics, Western blotting, qPCR, and metabolic flux analysis. After treating cells with the ornithine decarboxylase inhibitor DFMO and then restoring spermidine, they tracked changes across more than 6,700 proteins by nano LC-MS/MS. Their results pointed not to healthier mitochondrial metabolism, but to enhanced glycolysis: polyamines increased expression of proteins linked to cancer-associated glucose metabolism, including PDK1 and PKM2, while extracellular acidification and oxygen-consumption assays showed a stronger effect on glycolytic activity than on mitochondrial respiration.

The key mechanistic finding was a divergence between the closely related proteins eIF5A1 and eIF5A2. “The biological activity of polyamines via eIF5A differs between normal and cancer tissues,” said co-author Kyohei Higashi in a press release. “In normal tissues, eIF5A1, activated by polyamines, activates mitochondria via autophagy, whereas in cancer tissues, eIF5A2, whose synthesis is promoted by polyamines, controls gene expression at the translational level to facilitate the proliferation of cancer cells.”

The team showed that polyamines boost eIF5A2 at the translational level by interfering with the suppressive action of miR-6514-5p at the 5′ untranslated region of eIF5A2 mRNA. Silencing eIF5A2 inhibited proliferation more strongly than silencing eIF5A1 in cervical and breast cancer cell lines, while proteomic profiling suggested that the two proteins regulate different subsets of targets. Polyamines also increased several ribosomal proteins associated with malignancy, including RPS27A, RPL36A/L, and RPL22L1.

“Our findings reveal an important role for eIF5A2, regulated by polyamines and miR-6514-5p, in cancer cell proliferation,” Higashi said, adding that the interaction between eIF5A2 and ribosomes could offer “a selective target for cancer treatment.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

The Analytical Scientist Innovation Awards 2024: #7
Omics
The Analytical Scientist Innovation Awards 2024: #7

December 2, 2024

4 min read

Frank Steemers, co-founder and CSO of Scale Biosciences, tells us the story of ScalePlex – the 7th ranked innovation on this year’s Awards

The Analytical Scientist Innovation Awards 2024: #4
Omics
The Analytical Scientist Innovation Awards 2024: #4

December 5, 2024

6 min read

Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

Let Me See That Brain
Omics
Let Me See That Brain

December 9, 2024

1 min read

TRISCO sets a new standard for 3D RNA imaging, delivering high-resolution and uniform images to offer insights into brain function and anatomy

The Analytical Scientist Innovation Awards 2024
Omics
The Analytical Scientist Innovation Awards 2024

December 11, 2024

10 min read

Meet the products – and the experts – defining analytical innovation in 2024

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.